1. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real‐life experience. Issue 1 (1st November 2021) Authors: Massaro, Fulvio; Pavone, Vincenzo; Stefani, Piero Maria; Botto, Barbara; Pulsoni, Alessandro; Patti, Caterina; Cantonetti, Maria; Visentin, Andrea; Scalzulli, Potito Rosario; Rossi, Andrea; Galimberti, Sara; Cimminiello, Michele; Gini, Guido; Musso, Maurizio; Sorio, Marco; Arcari, Annalisa; Zilio... Journal: Hematological oncology Issue: Volume 40:Issue 1(2022) Page Start: 32 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?. (19th September 2018) Authors: Latagliata, Roberto; Breccia, Massimo; Carmosino, Ida; Cesini, Laura; De Benedittis, Daniela; Mohamed, Sara; Vozella, Federico; Molica, Matteo; Campanelli, Melissa; De Luca, Maria Lucia; Colafigli, Gioia; Quattrocchi, Luisa; Loglisci, Maria Giovanna; Massaro, Fulvio; Canichella, Martina; Diverio,... Journal: European journal of haematology Issue: Volume 101:Number 5(2018) Page Start: 578 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Current first- and second-line treatment options in acute promyelocytic leukemia. (November 2016) Authors: Massaro, Fulvio; Molica, Matteo; Breccia, Massimo Journal: International journal of hematologic oncology Issue: Volume 5:Number 3(2016) Page Start: 105 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Diagnostic and prognostic cytogenetics of chronic myeloid leukaemia: an update. (2nd November 2017) Authors: Molica, Matteo; Massaro, Fulvio; Breccia, Massimo Journal: Expert review of molecular diagnostics Issue: Volume 17:Number 11(2017) Page Start: 1001 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Early molecular response in chronic myeloid leukemia and halving time: Latest evidences. (September 2016) Authors: Breccia, Massimo; Molica, Matteo; Colafigli, Gioia; Massaro, Fulvio; Alimena, Giuliana Journal: Leukemia research Issue: Volume 48(2016:Sep.) Page Start: 20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Early molecular response in chronic myeloid leukemia and halving time: Latest evidences. (September 2016) Authors: Breccia, Massimo; Molica, Matteo; Colafigli, Gioia; Massaro, Fulvio; Alimena, Giuliana Journal: Leukemia research Issue: Volume 48(2016:Sep.) Page Start: 20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety. (23rd July 2016) Authors: Perrone, Salvatore; Massaro, Fulvio; Alimena, Giuliana; Breccia, Massimo Journal: Expert opinion on pharmacotherapy Issue: Volume 17:Number 11(2016) Page Start: 1517 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes. Issue 2 (1st February 2017) Authors: Massaro, Fulvio; Molica, Matteo; Breccia, Massimo Journal: Expert review of hematology Issue: Volume 10:Issue 2(2017) Page Start: 155 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Long‐term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib. (17th February 2017) Authors: Molica, Matteo; Breccia, Massimo; Colafigli, Gioia; Massaro, Fulvio; Quattrocchi, Luisa; Mancini, Marco; Diverio, Daniela; Latagliata, Roberto; Foà, Robin Journal: British journal of haematology Issue: Volume 181:Number 2(2018) Page Start: 275 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Long‐term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high‐dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma. (14th May 2020) Authors: Massaro, Fulvio; Stepanishyna, Yana; Manni, Martina; Luminari, Stefano; Galimberti, Sara; Marcheselli, Luigi; Visco, Carlo; Tecchio, Cristina; Stelitano, Caterina; Angrilli, Francesco; Petrini, Mario; Merli, Francesco; Federico, Massimo Journal: British journal of haematology Issue: Volume 192:Number 6(2021) Page Start: 1011 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗